ERBB2 and breast cancer: Indeed, the main studies exploring the prognostic value of SUV of the primary lesion in BC patients included various biological subgroups (i.e. luminal HER2-negative, HER2-positive and basal), whereas in the present study only luminal HER2-negative BC were concerned [28].